FDA approves Lamzede (velmanase alfa-tycv) for patients with alpha-mannosidosis

Lamzede (velmanase alfa-tycv) is the first enzyme replacement therapy approved for the treatment of non-CNS manifestations of alpha-mannosidosis in adult and pediatric patients. Alpha-mannosidosis is a rare lysosomal storage disorder caused by a deficiency of the enzyme α-mannosidase.